The efficacy of [68Ga]Ga-FAPI-02, the first generation of FAP inhibitors was investigated in comparison with the reference standard [18F]FDG in patients with breast, lung, and pancreatic cancer metastases. Here, FAP is linked to familial pancreatic carcinoma.